Sulfonylureas Market Report Scope & Overview:

The Sulfonylureas Market size is valued at USD 8.89 Billion in 2025 and is projected to reach USD 12.16 Billion by 2035, growing at a CAGR of 3.20% during the forecast period 2026–2035.

The Sulfonylureas Market analysis report provides in-depth evaluation of patterns in therapy use, prescription patterns, and pharmaceutical industry competition. The rise in the number of diabetes cases, need for cost-effective oral hypoglycemic agents, rise in treatment options, and better treatment options for diabetes are propelling the growth rate during 2026-2035.

Sulfonylureas prescriptions exceeded 160 million in 2025, driven by their cost-effective use in type 2 diabetes treatment.

Market Size and Forecast:

• Market Size in 2025: USD 8.89 Billion

• Market Size by 2035: USD 12.16 Billion

• CAGR: 3.20% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

Sulfonylureas Market Trends:

• Rising prevalence of type 2 diabetes is increasing long-term demand for affordable oral antidiabetic therapies such as sulfonylureas.

• Strong preference for cost-effective generic diabetes medications is sustaining market growth, particularly in emerging healthcare markets.

• Increasing use of combination therapies with metformin and other antidiabetic drugs is expanding clinical applications of sulfonylureas.

• Expanding diabetes screening, awareness programs, and early diagnosis initiatives are boosting prescription rates.

• Continuous pharmaceutical formulation improvements and extended-release tablets are enhancing treatment adherence and patient outcomes.

• Growing healthcare infrastructure and pharmacy accessibility in developing regions is strengthening distribution and market penetration of sulfonylurea drugs.

U.S. Sulfonylureas Market Insights:

The U.S. Sulfonylureas Market is projected to grow from USD 2.80 Billion in 2025 to USD 3.61 Billion by 2035, at a CAGR of 2.59%. This growth is attributed to the high prevalence rate of type 2 diabetes, the continued use of cost-effective oral therapies for diabetes, high prescription rates for sulfonylureas, and the existing pharmaceutical distribution infrastructure in the United States.

Sulfonylureas Market Growth Drivers:

• Surging type 2 diabetes prevalence accelerating demand for affordable, widely prescribed sulfonylurea oral therapies.

Rising prevalence of type 2 diabetes is a major driver of the Sulfonylureas Market growth. The drugs are also favored due to their proven efficacy in reducing the level of blood glucose and cost-effectiveness as a drug for the treatment of diabetes compared to newer antidiabetic drugs. Healthcare practitioners also favor sulfonylureas as second-line therapy for the treatment of diabetes. Increasing diabetes screening activities, improved healthcare service delivery in developing countries, and the need for cost-effective long-term treatment options for diabetes also contribute to the growth of the sulfonylurea drug market.

Over 58% of type 2 diabetes patients in emerging markets relied on sulfonylurea-based therapies in 2025 due to their affordability and established clinical effectiveness.

Sulfonylureas Market Restraints:

• Rising adoption of newer antidiabetic drug classes such as SGLT2 inhibitors and GLP-1 therapies limiting sulfonylurea demand.

Rising adoption of newer antidiabetic drug classes is a key restraint for the Sulfonylureas Market. The current therapies such as SGLT2 inhibitors and GLP-1 receptor agonists are increasingly being preferred over others due to the added advantages of weight loss and reduced hypoglycemia. There is a trend seen among a large number of practitioners to gradually move toward the latest therapies. Due to the changing guidelines and development of new drugs, the trend of the latest drugs may act as a hindrance to the growth of traditional SU drugs.

Sulfonylureas Market Opportunities:

• Expanding diabetes diagnosis rates in emerging economies creating strong opportunities for affordable sulfonylurea-based treatment adoption.

Expanding diabetes diagnosis rates in emerging economies present a major opportunity for the Sulfonylureas Market. Developing countries are also enhancing their methods of detecting diabetes in patients. As the number of patients diagnosed with type 2 diabetes is growing, so is the need for oral medication that can be afforded by all. Sulfonylureas are used, as they are affordable and have been proven effective in the management of the condition. The new healthcare system, and the government’s initiatives in the management of diabetes, are expected to increase the demand for sulfonylurea drugs.

Over 61% of newly diagnosed type 2 diabetes patients in emerging economies received sulfonylurea-based therapy in 2025 due to affordability and broad availability.

Sulfonylureas Market Segmentation Analysis:

• By Drug Type, Glimepiride held the largest market share of 28.47% in 2025, while Gliclazide is expected to grow at the fastest CAGR of 7.26% during 2026–2035.

• By Drug Generation, Second-Generation Sulfonylureas accounted for the highest market share of 82.63% in 2025 and are also projected to register the fastest CAGR of 6.92% through 2026–2035.

• By Indication, Type 2 Diabetes Mellitus dominated with an 88.54% market share in 2025, while Metabolic Syndrome is expected to grow at the fastest CAGR of 6.71% during the forecast period.

• By Dosage Form, Tablets held the largest share of 79.38% in 2025, whereas Oral Suspension is anticipated to expand at the fastest CAGR of 7.14% through 2026–2035.

• By Distribution Channel, Retail Pharmacies captured the highest market share of 66.41% in 2025, while Online Pharmacies are expected to grow at the fastest CAGR of 8.36% during the forecast period.

By Drug Type, Glimepiride Dominated While Gliclazide Is Fastest Growing:

Glimepiride segment accounted for the largest share of the market due to the large number of prescriptions, glucose-lowering properties, and the fact that it is a low-cost drug. In 2025, there were over 72 million prescriptions associated with the drug.

Gliclazide is the fastest growing segment owing to its improved safety profile and lower risk of hypoglycemia. It also offers better cardiovascular safety and consistent glycemic control. Increasing physician preference for safer sulfonylureas supported its growth, with over 28 million prescriptions recorded in 2025.

By Drug Generation, Second-Generation Sulfonylureas Dominated While Also Fastest Growing:

Second Generation Sulfonylureas dominated the market due to the increased potency and pharmacokinetic properties with fewer side effects compared to first-generation drugs. Second Generation Sulfonylureas are also recommended for the management of type 2 diabetes. In the year 2025, more than 180 million treatment courses included second-generation drugs.

Second Generation Sulfonylureas also holds the highest growth rate among all segments. The first-generation drugs are facing a decline, but second-generation drugs are increasing with more than 5 million patient additions in the year 2025.

By Indication, Type 2 Diabetes Mellitus Dominated While Metabolic Syndrome Is Fastest Growing:

Type 2 Diabetes Mellitus segment dominated this market due to a high disease burden and a central role of sulfonylureas in managing this disease. This class of drugs is commonly prescribed to manage this disease in a long-term manner. In 2025, more than 210 million patients with type 2 diabetes are being managed with sulfonylurea therapy.

Metabolic Syndrome is the fastest-growing segment, driven by the increase in early-stage interventions and preventive treatments. The widening focus on comorbidity management is fueling the adoption trends as well. The growing awareness and diagnosis are contributing factors, leading to more than 35 million cases of treatments associated with metabolic syndrome in 2025.

By Dosage Form, Tablets Dominated While Oral Suspension Is Fastest Growing:

Tablets segment dominated the market owing to the ease, stability, and cost-effectiveness of the administration of drugs for diabetes. These are easily available and well-accepted by patients and healthcare providers. In the year 2025, more than 240 billion tablets of sulfonylureas were consumed.

Oral Suspension is the segment with the highest growth rate, driven by the demand from the aging population and children with difficulty in swallowing. Ease of administration is a factor that boosts patient compliance. This segment is growing with increasing adoption, with over 18 million units being administered in 2025.

By Distribution Channel, Retail Pharmacies Dominated While Online Pharmacies Are Fastest Growing:

Retail Pharmacies accounted for the maximum share of the market due to their high accessibility, established supply chain, and widespread geographical presence. Patients use retail pharmacies to refill their medications. In 2025, prescriptions dispensed through retail pharmacies for sulfonylureas were more than 65%, totaling over 190 million.

Online Pharmacies is the fastest-growing segment, and this is due to the increasing rate of adoption of digital health. The rapid growth of smartphone usage is helping the accessibility of digital prescriptions. In 2025, the online channel is expected to serve over 48 million orders for sulfonylurea drugs.

Sulfonylureas Market Regional Analysis:

North America Sulfonylureas Market Insights:

The North America Sulfonylureas Market is dominated, holding a 38.72% share in 2025, driven by the presence of advanced healthcare infrastructure and the high prevalence of type 2 diabetes. Robust prescription rates for cost-effective antidiabetics also contribute positively. The presence of major companies and the availability of retail pharmacies are also growth factors. Moreover, the presence of treatment guidelines and the increasing use of combination therapies make the North American market an important and mature market.

U.S. Sulfonylureas Market Insights:

The U.S. Sulfonylureas Market is fueled by the prevalence of type 2 diabetes treatment and the robust usage of cost-effective oral drugs in hospitals and clinics. Existing pharmaceutical infrastructure and retail pharmacy penetration are also supporting factors for the US market. Increasing trends of combination therapies and optimization are also helping the US market to retain its top position as the market leader in the North American market.

Asia-Pacific Sulfonylureas Market Insights:

The Asia-Pacific Sulfonylureas Market is the fastest-growing region, projected to expand at a CAGR of 4.98% during 2026–2035. Growth is driven by the increased incidence rate of type 2 diabetes, expansion in healthcare infrastructure, and availability of affordable medicines in China, India, Japan, and Southeast Asia. Government initiatives in diabetes screening programs and availability of generic medicines and expansion in pharmaceutical networks are also contributing to the growth of this market in the Asia-Pacific region.

China Sulfonylureas Market Insights:

The China Sulfonylureas Market is driven by factors such as increasing healthcare infrastructure, high prevalence of type 2 diabetes, and strong domestic production of generic drugs. Easy availability of drugs, affordability, and extensive pharmaceutical store networks would further boost demand. Government initiatives would ensure that China contributes substantially to regional market growth.

Europe Sulfonylureas Market Insights:

The Europe Sulfonylureas Market is backed by an already developed healthcare system, robust pharmaceutical manufacturing industry, and an increasing number of diabetics in the region. Countries such as Germany, France, and the UK are major contributors to this segment due to their consistent prescription of oral antidiabetics. The increasing focus on cost-effective management of diabetes, availability of generic drugs, and the increasing focus on patient care strategies are also helping this region grow further.

Germany Sulfonylureas Market Insights:

Germany is a key market in the Europe Sulfonylureas Market, backed by well-developed health infrastructure and a well-developed pharmaceutical industry. Growth is driven by high prevalence of type 2 diabetes, consistent use of cost-effective oral therapies, stringent clinical guidelines, and widespread availability of generic sulfonylureas through hospital and retail pharmacy networks.

Latin America Sulfonylureas Market Insights:

The Latin America Sulfonylureas Market is growing due to the rise in healthcare infrastructure and type 2 diabetes. Countries such as Brazil, Mexico, and Argentina are witnessing a rise in the need for cost-effective oral antidiabetic agents. In this region, a rise in the number of pharmacies and healthcare schemes is favoring the growth of this market.

Middle East and Africa Sulfonylureas Market Insights:

The Middle East & Africa Sulfonylureas Market is expanding due to improving health care infrastructures and increasing incidence rates of diabetes. Growing needs for cost-effective oral anti-diabetic medicines in health care institutions are fueling this growth. Expanding pharmaceutical networks and government health programs in emerging markets such as Saudi Arabia, UAE, and South Africa are also boosting regional markets.

Sulfonylureas Market Competitive Landscape:

Sanofi is a pharmaceutical giant that has a significant footprint in diabetes care and a well-established portfolio of oral antidiabetic agents that include sulfonylureas. The company has been a market leader in this segment due to its widespread distribution network and brand recognition, and its relentless commitment to providing affordable solutions for diabetes management. Its operations in both developed and emerging markets have helped the company sustain its position in the market for sulfonylureas and diabetes management in general.

• In February 2025, Sanofi launched its insulin biosimilar Merilog, expanding its diabetes portfolio with a cost-effective alternative, strengthening accessibility, improving treatment affordability, and reinforcing its leadership in diabetes therapeutics markets.

Pfizer Inc. is a renowned multinational pharmaceutical corporation with a wide range of therapeutic areas, especially in the metabolic and endocrine segment. Pfizer has managed to sustain its market share in the sulfonylureas segment with its wide presence, manufacturing strength, and provision of both generic and brand products. Pfizer’s market leadership is a result of its commitment to research-driven healthcare, association with healthcare professionals, and wide distribution network, thus ensuring a constant demand for cost-effective oral antidiabetic agents.

• In February 2026, Pfizer Inc. announced commercialization of ecnoglutide in China, expanding its diabetes pipeline, improving access to advanced therapies, strengthening regional presence, and enhancing its competitive position in metabolic disease treatment markets.

Merck & Co., Inc. is a prominent pharmaceutical company with an already established presence in the field of diabetes and metabolic disorders. The company has further solidified its position in the sulfonylureas market through its focus on innovation, quality drug manufacture, and extensive presence. Merck’s strong clinical capabilities and investment in diabetes care have helped the company maintain its competitive edge in the market. The company’s focus on effective and accessible therapies further emphasizes its continued influence in the diabetes treatment market.

• In March 2025, Merck & Co., Inc. advanced development of efinopegdutide, targeting metabolic and diabetes-related conditions, reinforcing its innovation pipeline, strengthening long-term growth strategy, and enhancing its presence in next-generation diabetes therapeutics.

Sulfonylureas Market Key Players:

Some of the Sulfonylureas Market Companies are: 

• Sanofi

• Pfizer Inc.

• Merck & Co., Inc.

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

• Mylan N.V. (Viatris)

• Sun Pharmaceutical Industries Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Aurobindo Pharma Ltd.

• Zydus Lifesciences Ltd.

• Cipla Ltd.

• Torrent Pharmaceuticals Ltd.

• Lupin Limited

• Hikma Pharmaceuticals PLC

• Amneal Pharmaceuticals LLC

• Boehringer Ingelheim International GmbH

• AstraZeneca plc

• Eli Lilly and Company

• Glenmark Pharmaceuticals Ltd.

• Biocon Ltd.